Trial Profile
INvestigating COPD Outcomes, Genomics and Neutrophilic Inflammation With Tiotropium and Olodaterol
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 05 Nov 2021
Price :
$35
*
At a glance
- Drugs Olodaterol/tiotropium bromide (Primary) ; Vilanterol/fluticasone furoate (Primary)
- Indications Chronic obstructive pulmonary disease
- Focus Therapeutic Use
- Acronyms INCOGNIOT
- 04 Feb 2020 Status changed from recruiting to completed.
- 04 Apr 2019 Planned End Date changed from 1 Dec 2018 to 1 Dec 2019.
- 04 Apr 2019 Planned primary completion date changed from 1 Dec 2018 to 1 Dec 2019.